Table 2.
Cardiovascular events among propensity score-matched MSU crystal exposed and unexposed individuals
| MSU crystals | No MSU crystals | HR (95 % CI) | HR (95 % CI) | |
|---|---|---|---|---|
| (events / person-year) | (events / person-year) | no stratification by urate level | stratified by urate level | |
| APTC | 46 / 1026 | 34 / 1009 | 1.33 (0.85–2.07) | 0.86 (0.52–1.43) |
| Nonfatal MI | 11 / 1026 | 9 / 1009 | 1.22 (0.50–2.94) | 1.04 (0.37–2.90) |
| Nonfatal stroke | 17 / 1026 | 11 / 1009 | 1.50 (0.70–3.20) | 1.13 (0.49–2.61) |
| CV death | 18 / 1026 | 14 / 1009 | 1.27 (0.63–2.56) | 0.59 (0.26–1.32) |
| All-cause mortality | 46 / 1026 | 40 / 1009 | 1.14 (0.75–1.74) | 0.74 (0.45–1.21) |
APTC AntiPlatelet Trialists’ Collaboration, CI confidence interval, CV cardiovascular, HR Hazard ratio, MI myocardial infarction, MSU monosodium urate
The no-crystal group was set as reference